For the latest news and information on the coronavirus pandemic, visit the WHO website.
Political pressure to approve a vaccine before election day has grown so great that nine of the best-known biopharmaceutical companies currently working on a COVID-19 vaccine are signing a letter pledging to fully review their experimental drugs before asking for government approval. And while this seems like a given, Russia already approved a vaccine before it was thoroughly tested, and China has started giving a vaccine to military and health workers despite incomplete testing.
Seven vaccine candidates are currently being tested in the United States, three of which are nearing the terminal stage required for approval by the Food and Drug Administration. Given that SARS-CoV-2 – the virus that causes COVID-19 – was only discovered eight months ago, the advance in infectious disease history is actually faster than ever, despite Trump’s claim that it is vaccine development is deliberately stifled (vaccine development takes an average of 10.7 years).
Here we are examining the current landscape for an evolving coronavirus vaccine. This article is updated frequently and is intended to provide a general overview, not a source of medical advice. If you need more information about coronavirus testing, you can find a testing site near you here.
Important news about COVID-19 vaccines
A large coronavirus vaccine study has been suspended and the start of US testing has been delayed While scientists investigate whether a case of spinal inflammation in a volunteer is related to the vaccine developed by Oxford University and AstraZeneca.
Pfizer and BioNTech believe they can have a coronavirus vaccine ready For approval by October or November, according to Ugur Sahin, Co-Founder and CEO of BioNTech.
“We are unlikely to have a final answer” until the November 3rd electionAccording to Dr. Anthony Fauci, the leading US infectious disease officer.
Most people in the US won’t be able to get a vaccine until 2021, even if one or more are approved before the end of 2020, according to an early draft of a possible vaccination schedule released by the National Academy of Sciences in August.
Mexico could have its own coronavirus vaccine by springAccording to a researcher tasked with coordinating the country’s efforts, he said the drug will go through a full three-phase review process before it is approved.
New York State coronavirus The positivity rate has dropped to 1% For 30 days after one of the worst outbreaks in the country fell.
A nationwide shortage of dry ice could slow coronavirus vaccine distributionSome vaccine candidates require sub-zero temperatures while in storage, according to Boston NPR news network.
The development of COVID vaccines is getting faster and faster
Various acceleration efforts are currently underway, such as the White House’s Operation Warp Speed, which aims to cut red tape in order to speed up vaccine development and be ready to distribute vaccines once they get FDA approval. So far, the U.S. government has pledged over $ 10 billion to several vaccine manufacturers for a total of 800 million vaccine doses.
Vaccines usually take around 10 to 15 years to develop and approve. This is done in four phases, which include human experiments. However, with Operation Warp Speed, approved vaccine projects cannot submit all sections of the application after completing all four phases, but can gradually submit data to the FDA.
In the meantime, the program is also funding efforts to begin making cans while clinical trials are ongoing. That is, by the time these vaccines are approved, there will already be a supply of doses that can be distributed nationally. “I would hope that companies will have delivered the hundreds of millions of doses promised by well into the second half of 2021,” said Dr. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, told Forbes in August.
Promising coronavirus vaccines from the UK, US and China
Here’s a quick look at some of the frontrunners in the race for a vaccine against COVID-19, including where the vaccines are being developed, where they’re being tested, and when scientists think they’re ready for widespread adoption, if known.
Oxford University / AstraZeneca (Great Britain): AstraZeneca has suspended testing of its vaccine, which it began on 100,000 volunteers in at least three countries, and which was preparing to launch in the United States. The lead researcher Dr. Sarah Gilbert had originally said that they are aiming for a release in the fall of 2020, which may now be delayed. However, UK Health Secretary Matt Hancock said such a hiatus was “not necessarily” a setback.
Moderna (USA): An apparent dispute with state regulators delayed large-scale human testing, but Moderna’s CEO has told Barron’s that he continues to expect the company to know if the vaccine is safe and effective by Thanksgiving, and to begin selling it in early 2021 can if this is the case.
Pfizer (USA): Although the four COVID-19 vaccine candidates are still in early human trials, two of them have been accelerated by the FDA. Pfizer’s chief business officer told US Congress that the company may be ready to file for FDA approval by October.
SinoVac (China): The vaccine is currently being tested on around 10,000 volunteers in China and around 9,000 in Brazil. Approximately 1,900 subjects are to be tested in Indonesia shortly. The CEO of BioPharma, SinoVac’s Indonesian partner, expects the vaccine to be ready in early 2021.
SinoPharm (China): The state-owned company is currently testing around 15,000 volunteers in the Middle East in a test that is expected to take three to six months. Initial results suggest that the drug is safe and at least reasonably effective. SinoPharm recently built a second facility to manufacture the vaccine and doubled its capacity to around 200 million doses per year.
CanSino Biologics (China): CanSino’s vaccine is slated to begin large-scale human trials this summer and has already been approved for the Chinese military. The vaccine is based on a modified cold virus that some experts warn may be less effective than other vaccine efforts.
Will there be only one vaccine for everyone?
We probably won’t know until next year, but Fauci has suggested that several different vaccines, made and sold by different laboratories, might be needed to end the pandemic. This was published in an article published in Science magazine on May 11th.
What if we never find a coronavirus vaccine?
Coronaviruses are a large class of viruses and there are currently no vaccines for any of them. While there are promising early results, there is no guarantee of a vaccine by 2021. Statistically, only about 6% of vaccine candidates ever make it to market, according to a Reuters special report.
Early evidence suggests that the coronavirus doesn’t seem to mutate as quickly or frequently as the flu, and it is believed that the virus has not yet mutated significantly enough to disrupt vaccine development – although our knowledge may change.
The longer we go without a vaccine, the more likely the focus will be on treatments like that, which has reportedly shown promising results, and , a steroid that doctors say increases survival rates among the most serious of cases. With effective therapeutic treatments, many viruses that used to be fatal are no longer death sentences. For example, thanks to tremendous advances in treatment, patients with HIV can now expect the same life expectancy as non-HIV positive people.
Eventually the world population may reach the rate required for 60% to 70%Protecting those who are not immune, which is the ultimate goal of a vaccine.